ERBB2 and non-small cell lung carcinoma: Furthermore, recently, at the last American Society of Clinical Oncology (ASCO) annual meeting, the preliminary analysis of cohort F (39 patients with HER2 MUT NSCLC naïve for systemic therapy) was presented with an ORR of 59% and a DCR of 84.6% [84].